KRX.C covers this -1.5 handicap with high confidence. Their early game dominance is a glaring disparity against BFY's consistent macro liabilities. KRX.C boasts a +1200 GD@15 and a 68% FB rate over their last five series, directly translating to superior objective control (65% Dragon Rate). BFY, conversely, consistently posts a -800 GD@15 and a 45% FB rate, often hemorrhaging early leads and conceding neutral objectives. While their last H2H was a 2-1, that was an anomaly; KRX.C historically secures 2-0 sweeps against teams with sub-par vision scores and weak mid-game shotcalling like BFY. The market underestimates KRX.C's capacity to exploit BFY's predictable power curve dips. This is a clear mispricing on the series sweep. 90% YES — invalid if KRX.C's jungler fails to secure First Blood or has a significant pathing error in game one.
KRX.C covers this -1.5 handicap with high confidence. Their early game dominance is a glaring disparity against BFY's consistent macro liabilities. KRX.C boasts a +1200 GD@15 and a 68% FB rate over their last five series, directly translating to superior objective control (65% Dragon Rate). BFY, conversely, consistently posts a -800 GD@15 and a 45% FB rate, often hemorrhaging early leads and conceding neutral objectives. While their last H2H was a 2-1, that was an anomaly; KRX.C historically secures 2-0 sweeps against teams with sub-par vision scores and weak mid-game shotcalling like BFY. The market underestimates KRX.C's capacity to exploit BFY's predictable power curve dips. This is a clear mispricing on the series sweep. 90% YES — invalid if KRX.C's jungler fails to secure First Blood or has a significant pathing error in game one.
